Gastrointestinal
Iterative Health and FRI partner to introduce AIR technology in Florida, US
Iterative Health and the Florida Research Institute (FRI) in the US have collaborated to introduce the former’s artificial intelligence (AI)-Recruitment…
Pipeline Moves: positive topline results for epilepsy drug, advancement prospects jump
This week on Pipeline Moves, we start off on a good note by looking at positive topline results from a…
Inflammatory bowel disease trials: addressing the challenge of declining enrolment
Declining enrolment rates have become a key challenge for clinical trials recruiting patients with inflammatory bowel disease (IBD), reveals a…
First Wave BioPharma to initiate trial of adrulipase for cystic fibrosis
First Wave BioPharma is set to initiate its Phase II clinical trial of an improved adrulipase formulation in exocrine pancreatic…
AltruBio doses first subject in Phase I ulcerative colitis therapy trial
AltruBio has dosed the first subject in a Phase I clinical trial of its next-generation PSGL-1 antibody agonist, ALTB-268, in…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Renexxion reveals clinical development plans to address GI symptoms in cystic fibrosis patients
Renexxion is gearing up for two Phase II trials investigating naronapride in patients with cystic fibrosis (CF) and gastrointestinal (GI)…
IMA acquires multi-therapeutic clinical trials company in the US
The IMA Group (IMA) has acquired multi-therapeutic company Clinical Trials of America (CTA) in the US. This acquisition will bring…
Pipeline Moves: AbbVie and Janssen terminate Phase III lymphoma trial, approval prospects plummet
This week on Pipeline Moves, we look into the terminations of two oncology clinical trials. We also review the positive…
Biocon commences Phase II trial of ulcerative colitis therapy
Equillium partner Biocon has commenced a Phase II clinical trial of itolizumab to treat ulcerative colitis (UC) patients. The placebo-controlled,…
Astellas’ Phase III gastric cancer therapy trial meets primary endpoint
Astellas Pharma has reported that the Phase III GLOW clinical trial of zolbetuximab plus CAPOX as a first-line therapy to treat Claudin 18.2…